Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria.

Akinobu NakamuraHideaki MiyoshiHiraku KamedaKumiko YamashitaYoshio Kurihara

Published in: Diabetology & metabolic syndrome (2020)

These results demonstrate that more favorable effects of SGLT2 inhibitors on renal function were observed in participants with type 2 diabetes and CKD with normoalbuminuria compared with those with macroalbuminuria.Trial registration UMIN-CTR: UMIN000035263. Registered 15 December 2018.

Keyphrases

chronic kidney disease
end stage renal disease
clinical trial
study protocol
phase iii
randomized controlled trial